Tredje AP fonden Trims Position in Illumina (ILMN)

Tredje AP fonden cut its stake in Illumina (NASDAQ:ILMN) by 2.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 76,476 shares of the life sciences company’s stock after selling 1,540 shares during the period. Tredje AP fonden owned about 0.05% of Illumina worth $18,080,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ILMN. Hemenway Trust Co LLC raised its holdings in shares of Illumina by 0.6% in the fourth quarter. Hemenway Trust Co LLC now owns 37,895 shares of the life sciences company’s stock valued at $8,280,000 after buying an additional 227 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Illumina by 4.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,543 shares of the life sciences company’s stock valued at $1,211,000 after buying an additional 229 shares during the last quarter. Howland Capital Management LLC raised its holdings in shares of Illumina by 5.3% in the first quarter. Howland Capital Management LLC now owns 5,014 shares of the life sciences company’s stock valued at $1,185,000 after buying an additional 254 shares during the last quarter. Fairfield Bush & CO. raised its holdings in shares of Illumina by 1.4% in the fourth quarter. Fairfield Bush & CO. now owns 18,985 shares of the life sciences company’s stock valued at $4,148,000 after buying an additional 255 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of Illumina by 38.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 993 shares of the life sciences company’s stock valued at $217,000 after buying an additional 278 shares during the last quarter. 91.59% of the stock is owned by hedge funds and other institutional investors.

Shares of Illumina stock opened at $268.67 on Thursday. Illumina has a 52-week low of $264.12 and a 52-week high of $267.94. The company has a current ratio of 2.71, a quick ratio of 2.41 and a debt-to-equity ratio of 0.23. The stock has a market cap of $38.77 billion, a PE ratio of 67.21, a PEG ratio of 2.71 and a beta of 0.86.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, April 24th. The life sciences company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.43. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The business had revenue of $782.00 million for the quarter, compared to analyst estimates of $744.30 million. During the same period in the previous year, the business posted $0.64 earnings per share. The business’s revenue was up 30.8% compared to the same quarter last year. equities analysts anticipate that Illumina will post 4.87 earnings per share for the current fiscal year.

In other Illumina news, EVP Omead Ostadan sold 1,329 shares of the company’s stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $222.66, for a total transaction of $295,915.14. Following the transaction, the executive vice president now directly owns 29,392 shares in the company, valued at $6,544,422.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Francis A. Desouza sold 2,100 shares of the company’s stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $268.63, for a total transaction of $564,123.00. Following the transaction, the chief executive officer now owns 87,371 shares in the company, valued at $23,470,471.73. The disclosure for this sale can be found here. Insiders have sold 18,022 shares of company stock worth $4,340,645 over the last 90 days. 0.54% of the stock is currently owned by company insiders.

A number of equities research analysts have recently commented on ILMN shares. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, March 10th. Morgan Stanley upped their target price on shares of Illumina from $170.00 to $180.00 and gave the company an “underweight” rating in a report on Wednesday, April 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $270.00 target price for the company in a report on Monday, April 16th. Citigroup raised shares of Illumina from a “neutral” rating to a “buy” rating and upped their target price for the company from $260.00 to $275.00 in a report on Monday, February 5th. Finally, Barclays upped their target price on shares of Illumina from $215.00 to $235.00 and gave the company an “equal weight” rating in a report on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $251.14.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply